COVID-19 Impact on Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2020-2026

August 2020 | 95 pages | ID: C99A7CD982B8EN
QYResearch

Abstracts

This report focuses on the global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Novartis
• Kite Pharma
• Juno Therapeutics
• Cellectis
• Ziopharm Oncology
• Celyad
• Bluebird Bio
• Bellicum Pharmaceuticals
• Mustang Bio

Market segment by Type, the product can be split into

• CAR T-cell Therapy
• TCR T-cell Therapy

Market segment by Application, split into

• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• B Cell Lymphoma
• Multiple Myeloma
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players.
• To present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Gene Modifying Immunotherapy for Blood Cancer are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
1.4 Market Analysis by Type
  1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 CAR T-cell Therapy
  1.4.3 TCR T-cell Therapy
1.5 Market by Application
  1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2020 VS 2026
  1.5.2 Acute Lymphocytic Leukemia
  1.5.3 Chronic Lymphocytic Leukemia
  1.5.4 B Cell Lymphoma
  1.5.5 Multiple Myeloma
  1.5.6 Other
1.6 Coronavirus Disease 2019 (Covid-19): Gene Modifying Immunotherapy for Blood Cancer Industry Impact
  1.6.1 How the Covid-19 is Affecting the Gene Modifying Immunotherapy for Blood Cancer Industry
    1.6.1.1 Gene Modifying Immunotherapy for Blood Cancer Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Gene Modifying Immunotherapy for Blood Cancer Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Gene Modifying Immunotherapy for Blood Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2015-2026)
2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
  2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Share by Regions (2015-2020)
  2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Gene Modifying Immunotherapy for Blood Cancer Market Growth Strategy
  2.3.6 Primary Interviews with Key Gene Modifying Immunotherapy for Blood Cancer Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Market Size
  3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2015-2020)
  3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2015-2020)
  3.1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
  3.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2019
3.3 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
3.4 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
3.5 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2015-2020)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2021-2026)

5 GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
6.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in North America (2019-2020)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
7.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Europe (2019-2020)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

8 CHINA

8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
8.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in China (2019-2020)
8.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
8.4 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
9.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Japan (2019-2020)
9.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
9.4 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
10.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

11 INDIA

11.1 India Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
11.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in India (2019-2020)
11.3 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
11.4 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
12.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
12.4 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Novartis
  13.1.1 Novartis Company Details
  13.1.2 Novartis Business Overview and Its Total Revenue
  13.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020))
  13.1.5 Novartis Recent Development
13.2 Kite Pharma
  13.2.1 Kite Pharma Company Details
  13.2.2 Kite Pharma Business Overview and Its Total Revenue
  13.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.2.5 Kite Pharma Recent Development
13.3 Juno Therapeutics
  13.3.1 Juno Therapeutics Company Details
  13.3.2 Juno Therapeutics Business Overview and Its Total Revenue
  13.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.3.5 Juno Therapeutics Recent Development
13.4 Cellectis
  13.4.1 Cellectis Company Details
  13.4.2 Cellectis Business Overview and Its Total Revenue
  13.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.4.5 Cellectis Recent Development
13.5 Ziopharm Oncology
  13.5.1 Ziopharm Oncology Company Details
  13.5.2 Ziopharm Oncology Business Overview and Its Total Revenue
  13.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.5.5 Ziopharm Oncology Recent Development
13.6 Celyad
  13.6.1 Celyad Company Details
  13.6.2 Celyad Business Overview and Its Total Revenue
  13.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.6.5 Celyad Recent Development
13.7 Bluebird Bio
  13.7.1 Bluebird Bio Company Details
  13.7.2 Bluebird Bio Business Overview and Its Total Revenue
  13.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.7.5 Bluebird Bio Recent Development
13.8 Bellicum Pharmaceuticals
  13.8.1 Bellicum Pharmaceuticals Company Details
  13.8.2 Bellicum Pharmaceuticals Business Overview and Its Total Revenue
  13.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.8.5 Bellicum Pharmaceuticals Recent Development
13.9 Mustang Bio
  13.9.1 Mustang Bio Company Details
  13.9.2 Mustang Bio Business Overview and Its Total Revenue
  13.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
  13.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
  13.9.5 Mustang Bio Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Gene Modifying Immunotherapy for Blood Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
Table 3. Ranking of Global Top Gene Modifying Immunotherapy for Blood Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of CAR T-cell Therapy
Table 6. Key Players of TCR T-cell Therapy
Table 7. COVID-19 Impact Global Market: (Four Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Gene Modifying Immunotherapy for Blood Cancer Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Gene Modifying Immunotherapy for Blood Cancer Players to Combat Covid-19 Impact
Table 12. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2015-2020)
Table 16. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Gene Modifying Immunotherapy for Blood Cancer Market Growth Strategy
Table 22. Main Points Interviewed from Key Gene Modifying Immunotherapy for Blood Cancer Players
Table 23. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2015-2020) (Million US$)
Table 24. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players (2015-2020)
Table 25. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2019)
Table 26. Global Gene Modifying Immunotherapy for Blood Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
Table 29. Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 32. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Type (2015-2020)
Table 33. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2021-2026)
Table 34. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Application (2015-2020)
Table 35. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 36. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Application (2021-2026)
Table 37. North America Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 39. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 40. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 41. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 42. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 43. Europe Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 45. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 47. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 49. China Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 50. China Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 51. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 52. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 53. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 54. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 55. Japan Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 57. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 59. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 63. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 65. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 67. India Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 68. India Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 69. India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 70. India Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 71. India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 72. India Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Gene Modifying Immunotherapy for Blood Cancer Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Gene Modifying Immunotherapy for Blood Cancer Market Share (2019-2020)
Table 75. Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2015-2020)
Table 77. Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2015-2020)
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Product
Table 82. Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 83. Novartis Recent Development
Table 84. Kite Pharma Company Details
Table 85. Kite Pharma Business Overview
Table 86. Kite Pharma Product
Table 87. Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 88. Kite Pharma Recent Development
Table 89. Juno Therapeutics Company Details
Table 90. Juno Therapeutics Business Overview
Table 91. Juno Therapeutics Product
Table 92. Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 93. Juno Therapeutics Recent Development
Table 94. Cellectis Company Details
Table 95. Cellectis Business Overview
Table 96. Cellectis Product
Table 97. Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 98. Cellectis Recent Development
Table 99. Ziopharm Oncology Company Details
Table 100. Ziopharm Oncology Business Overview
Table 101. Ziopharm Oncology Product
Table 102. Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 103. Ziopharm Oncology Recent Development
Table 104. Celyad Company Details
Table 105. Celyad Business Overview
Table 106. Celyad Product
Table 107. Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 108. Celyad Recent Development
Table 109. Bluebird Bio Company Details
Table 110. Bluebird Bio Business Overview
Table 111. Bluebird Bio Product
Table 112. Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 113. Bluebird Bio Recent Development
Table 114. Bellicum Pharmaceuticals Business Overview
Table 115. Bellicum Pharmaceuticals Product
Table 116. Bellicum Pharmaceuticals Company Details
Table 117. Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 118. Bellicum Pharmaceuticals Recent Development
Table 119. Mustang Bio Company Details
Table 120. Mustang Bio Business Overview
Table 121. Mustang Bio Product
Table 122. Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020) (Million US$)
Table 123. Mustang Bio Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Type: 2020 VS 2026
Figure 2. CAR T-cell Therapy Features
Figure 3. TCR T-cell Therapy Features
Figure 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2020 VS 2026
Figure 5. Acute Lymphocytic Leukemia Case Studies
Figure 6. Chronic Lymphocytic Leukemia Case Studies
Figure 7. B Cell Lymphoma Case Studies
Figure 8. Multiple Myeloma Case Studies
Figure 9. Other Case Studies
Figure 10. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
Figure 11. Global Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions: 2020 VS 2026
Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players in 2019
Figure 16. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2019
Figure 18. North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Novartis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 27. Kite Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Kite Pharma Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 29. Juno Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Juno Therapeutics Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 31. Cellectis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Cellectis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 33. Ziopharm Oncology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Ziopharm Oncology Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 35. Celyad Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Celyad Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 37. Bluebird Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Bluebird Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 39. Bellicum Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Bellicum Pharmaceuticals Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 41. Mustang Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Mustang Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed